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Lumbar spinal fusions have been performed for spinal
stability, pain relief and improved function in spinal stenosis,
scoliosis, spinal fractures, infectious conditions and other
lumbar spinal problems. The success of lumbar spinal fusion
depends on multifactors, such as types of bone graft materials,
levels and numbers of fusion, spinal instrumentation, electrical
stimulation, smoking and some drugs such as nonsteroidal
anti-inflammatory drugs (NSAIDs). From January 2000 to
December 2001, 88 consecutive patients, who were diagnosed
with spinal stenosis or spondylolisthesis, were retrospectively
enrolled in this study. One surgeon performed all 88
posterolateral spinal fusions with instrumentation and autoiliac
bone graft. The patients were divided into two groups. The first
group (n=30) was infused with ketorolac and fentanyl intra-
venously via patient controlled analgesia (PCA) postopera-
tively and the second group (n=58) was infused only with
fentanyl. The spinal fusion rates and clinical outcomes of the
two groups were compared. The incidence of incomplete union
or nonunion was much higher in the ketorolac group, and the
relative risk was approximately 6 times higher than control
group (odds ratio: 5.64). The clinical outcomes, which were
checked at least 1 year after surgery, showed strong correla-
tions with the spinal fusion status. The control group (93.1%)
showed significantly better clinical results than the ketorolac
group (77.6%). Smoking had no effect on the spinal fusion
outcome in this study. Even though the use of ketorolac after
spinal fusion can reduce the need for morphine, thereby
decreasing morphine related complications, ketorolac used via
PCA at the immediate postoperative state inhibits spinal fusion
resulting in a poorer clinical outcome. Therefore, NSAIDs
such as ketorolac, should be avoided after posterolateral spinal
fusion.
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INTRODUCTION
Lumbar spinal fusions are widely performed for
improving spinal stability and for pain relief. In
addition, these procedures show improved func-
tional outcomes in spinal stenosis, scoliosis, spinal
fractures, infectious conditions and other lumbar
spinal problems.
1-4 The success of lumbar spinal
fusion depends on many factors, such as the type
of bone graft materials, the level and number of
fusions, spinal instrumentation, electrical stimula-
tion, smoking, bone morphogenic proteins and
some drugs such as nonsteroidal anti-inflamma-
tory drugs (NSAIDs).
3-8
Ketorolac (Toradol, Roche Laboratories, Nurley,
NJ) is an NSAID, and has been largely used for
postoperative pain control via patient controlled
analgesia (PCA) after spinal fusion surgery in
order to reduce the need for morphine. Keto-
rolac's role in PCA is increasing.
9,10 Even though
NSAIDs have no influence on normal bone home-
ostasis, they have been reported to be associated
with a delayed fracture healing and the inhibition
of heterotopic ossification after a total hip arthro-
plasty.
11 In one animal study, indomethacin and
ibuprofen were reported to inhibit spine bone
union after spinal fusion surgery.
12-14
However, there have been no reports on the
influence of an intravenous ketorolac injection via
PCA on spinal fusion. This study retrospectively
compares the clinical outcomes and fusion rates of
ketorolac intravenous injected patients via PCA
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after spinal fusion surgery with those not injected
with ketorolac.
MATERIALS AND METHODS
The database of the Yonsei University Medical
College Severance Hospital Orthopaedic Depart-
ment was accessed to collect data on 88 consecu-
tive patients who had an instrumented postero-
lateral spinal fusion of the low lumbar spine
performed from January, 2000 to December, 2001
and who had been observed for a minimum of
one year after surgery. All patients underwent
posterolateral lumbar spine fusion procedures
using pedicle screws and a rod system and an
autologous iliac bone graft. All patients chose
PCA for their postoperative pain control after the
spinal fusion procedure. The PCAs of all patients
were managed by an anesthesiologist. The
patients pre-operative diagnoses were restricted to
spinal stenosis and spondylolisthesis, because of
the possible overuse of NSAIDs for postoperative
pain control. Patients were excluded from this
study if they had undergone a previous fusion
procedure or if their treatment included addi-
tional procedures, such as lumbar interbody
fusion or electrical stimulation. Cases in which
there were complicated problems such as difficult
operation techniques and problems associated
with the fusion procedure itself also, were ex-
cluded. Patients were also excluded from the
study based on the following criteria:
15
1. Documented allergy to aspirin or other
NSAIDs, morphine, meperidine
2. History of peptic ulcer disease, congestive
heart failure, liver disease, bleeding disorder
3. Concurrent medications including warfarin,
lithium, methotrexate
4. Hypoalbuminemia
The records of all 88 patients were examined for
their demographic data, including age, gender,
smoking history, diagnosis, level and the number
of fusions, the type of spinal instrument used, the
operation times, hospital days, and first post-
operative walking day. The patients were divided
into two groups. Group I was the ketorolac in-
fused group, Group II was the control group, not
given ketorolac. Patients in Group I were infused
with ketorolac via PCA after the spinal fusion
procedure. In the PCA, ketorolac 120 mg and
fentanyl 900μg were mixed and continuously
infused intravenously for postoperative pain
control. The PCA was removed approximately 3
days later. The patients in Group II were infused
via PCA with only fentanyl 1200μg. The PCA was
also removed after approximately 3 days. Follow-
up examinations were carried out at 3 months, 6
months, 1 year, and 2 years after surgery and at
least a 1 year follow-up was done for all patients.
At each visit, clinical symptoms were evaluated,
a physical examination was performed and radio-
logical assessments, such as the plain antero-
posterior view and the lateral view and a dyna-
mogram (flexion-extension view), were obtained.
The comparison between the two groups was
evaluated according to two categories.
Radiologic assessments
At least 1 year after surgery, the plain antero-
posterior views, the lateral views and the dyna-
mograms were evaluated by two orthopaedic
surgeons. Radiological fusion patterns were clas-
sified into one of the following four grades:
16
A) Definitely solid: Solid, big trabeculated bi-
laterally
B) Possibly solid: Solid, big fusion mass unila-
terally with a small fusion mass on contra-
lateral aspect
C) Probably not solid: Small, thin fusion masses
bilaterally with apparent crack
D) Definitely not solid (Pseudarthrosis): Graft
resorption bilaterally or fusion mass with an
obvious bilateral pseudarthrosis or breakage
of hardware
Probably not solid and definitely not solid are
considered nonunion.
Clinical assessments
At least 1 year after surgery, the clinical out-
comes were evaluated using the criteria reported
by Kim and Kim (Table 1).
17
Statistical analysis
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analyzed using a Fisher's exact test. The differ-
ences were considered to be significant at p < 0.05.
RESULTS
Among all 88 patients, 30 patients (Group I)
received ketorolac via PCA for approximately 3
days post surgery, and 58 patients (Group II)
received no ketorolac.
Demographic characteristics (Table 2)
Age and gender
The mean age of Group I and II was 54 (range,
20-66), and 52 (range, 28-67) respectively. There
was no significant difference in the age distri-
bution. Among the 88 patients, there were 29
males and 59 females. Group I consisted of 9
males and 21 females and Group II consisted of
20 males and 38 females.
Diagnosis
There were 50 spinal stenosis cases and 38
Table 1. Criteria for Clinical Outcomes
Excellent Complete relief of pain in back and lower lmbs
No limitation of physical activity
Analgesics not used
Able to squat on floor
Good Relief of most pain in back and lower limbs
Able to return to accustomed employment
Physical activities slightly limited
Analgesics used only infrequently
Able to squat on floor
Fair Partial relief of pain in back and lower limbs
Able to return to accustomed employment with limitation or return to lighter work
Physical activities definitely limited
Mild analgesics medication used frequently
Mild limitation to squat on floor
Poor Little or no relief of pain in back and lower limbs
Physical activities greatly limited
Unable to return to accustomed employments
Analgesics medication used regularly
Unable to squat on floor without support
Table 2. Demographic Characteristics
Group 1 Group 2
(with ketololac) (control)
Total number 30 58
Male 9 20
Female 21 38
Mean age (yr, range) 54 (20-66) 52 (28-67)
Smoking 6 9
Diagnosis
Spinal stenosis 17 33
Spondylolisthesis 13 25
Fusion levels
One level 23 39
L4/5 15 39
L5/S1 8 21
Two levels 7 19
Operation time (min) 175 182
Bleeding (ml) 650 690
First walking day 8
th day 8
th day
Hospital day 16 15
There was no statically difference between the two groups.Table 3. Radiologic Results
Group 1 Group 2
(with ketololac) (control)
Definitely solid 20 42
Probably solid 5 14
Probably not solid 3 1
Definitely not solid 2 1
Nonunion rates 5/30 2/58
(16.7%) (3.4%)
Table 4. Clinical Outcomes
Group 1 Group 2
(with ketololac) (control)
Excellent 5 (16.7%) 15 (25.9%)
Good 18 (60%) 39 (67.2%)
Fair 5 (16.7%) 3 (5.2%)
Poor 2 (6.6%) 1 (1.7%)
Satisifactory results 23 (76.7%) 54 (93.1%)
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spondylolisthesis cases. Group I contained 17 spi-
nal stenosis cases and 13 spondylolisthesis cases.
Group II contained 33 spinal stenosis cases and 25
spondylolisthesis cases. There was no statistically
significant difference in the diagnosis between the
two groups.
Levels and numbers of fusion
A one-level fusion was performed in 62 cases;
L5-S1 in 26 cases and the L4-5 was done in 36
cases. A two-level fusion was performed in 26
cases and all were fused from L4 - S1. In Group
I, there were 23 one-level fusion cases and 7 two-
level fusion cases. In Group II, there were 39 one-
level fusion cases and 19 twolevel fusion cases. In
Group I, there were 15 L4-L5 fusions, 8 L5-S1
fusions and 7 L4-S1 fusions. In Group II, there
were 21 L4-L5 fusions, 18 L5-S1 fusions, and 19
L4-S1 fusions. There was no significant difference
between the two groups.
Procedures of operation and rehabilitation
All operations were performed by the one
author (HML). After decompression, a spinal seg-
mental system was used and a posterolateral
spinal fusion with autoiliac bone was performed
on all patients. The types of spinal systems used
were Moss-Miami systems in 56 patients and
Synergy systems in 32 patients. The operation
time was almost the same for each group; 175
minutes for Group I, 182 minutes for Group II.
Blood loss through the procedures was about 650
ml in Group I and about 690 ml in Group II.
The same postoperative rehabilitation protocol
was used in both groups. The patients were sitting
up in bed for the first 3 days and out of bed with
a back brace at 7 days after the operation. All
patients were discharged from the hospital on
approximately the 14th day post-operatively. All
patients wore a back brace for 3 months.
Radiologic results (Table 3)
Nonunion, which met the criteria of probably or
definitely not solid, was identified in 5 out of the
30 patients (16.7%) who received ketorolac via
PCA, postoperatively. In contrast, nonunion was
identified in 2 out of the 58 patients (3.4%) who
did not receive ketorolac. There was a statistically
significant difference in the nonunion rate (p <
0.05) between each group; there was an approxi-
mately 6 times greater likelihood of developing a
nonunion with a ketorolac PCA than without
(odds ratio: 5.64). There was no significant differ-
ence in the nonunion rate between diagnoses
(spinal stenosis and spodylolisthesis).
Clinical outcomes (Table 4)
In Group I, the clinical results were excellent in
5 patients (16.7%), good in 18 patients (60%), fair
in 5 patients (16.7%), and poor in 2 patients
(6.6%). In Group II, the clinical results were excel-
lent in 15 patients (25.9%), good in 39 patients
(67.2%), fair in 3 patients (5.2%), and poor in 1
patient (1.7%).
Therefore, satisfactory results were obtained in
23 patients (77%) in Group I and 54 patients
(93.1%) in Group II. There was statistically a
significant difference between the two groups (p <
0.05). There was high correlation between fusion
and better clinical results.
DISCUSSION
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prescribed medication for the treatment of many
musculoskeletal diseases.
18 Many NSAIDs are
licensed for prescription use throughout the
world. The mechanism through which NSAIDs
exert their anti-inflammatory effect is the inhibi-
tion of the enzyme cyclo-oxygenase which is re-
sponsible for converting arachidonic acid to pros-
taglandin. NSAIDs also may exert their analgesic
effects by inhibiting prostaglandin synthesis,
because it is believed that the pain receptors are
prostaglandin sensitive. Recently, it was reported
that NSAIDs may use an alternative pathway to
achieve their anti-inflammatory and analgesic
effect, such as the inhibition of leukotriene pro-
duction, a blockade of oxygen-free radical forma-
tion, and interference with a protein-protein
interaction.
18,19 In addition, NSAIDs have been
shown to have a significant effect on bone metab-
olism.
12-14 Even though NSAIDs cannot alter the
normal bone homeostasis, they have been docu-
mented to inhibit fracture healing and decrease
heterotopic ossification after a total hip arthr-
oplasty. The mechanism of this action is believed
to be due to various etiologies, including the
inhibition of bone forming cells of the endosteal
bone surfaces, a reduction in the immune and in-
flammatory response or the inhibition of pros-
taglandin synthesis.
12,13 In an animal study, the
earlier the indomethacin was received post-
operatively, the greater its negative effect on
spinal fusion,
20 showing that this inhibitory effect
is potentially time-dependent. Indomethacin ap-
pears to play a significant inhibitory role in the
early phase of healing in the spinal fusion or
fracture healing process because it inhibits the
inflammatory reactions in the early inflammatory
phase. However, initiating indomethacin treat-
ment in the later phase of healing does not appear
to significantly affect the fusion rates.
20
Recently, there have been many studies on the
specific inhibitors of cyclo-oxygenase, such as
specific cyclooxygenase-2 inhibitors. Conventional
NSAIDs exhibited inhibitory effects on both
cyclooxygenase-1 (COX-1) and cyclooxygenase-2
(COX-2). However, the newly developed NSAIDs,
which are specific cyclooxygenase-2 (COX-2) inhi-
bitors, have recently been introduced to treat
musculoskeletal disorders. COX-1 has been re-
ported to be a housekeeping enzyme that is
constitutively expressed in virtually all tissues
under basal conditions. COX-1 regulates the pros-
taglandins that have a homeostatic function,
particularly in regards to gastrointestinal and
renal functions as well as platelet aggregation.
COX-2 expression is more highly regulated
compared with COX-1. COX-2 expression is rap-
idly inducible, particularly in instances of tissue
injury and inflammation.
21-25 Specific COX-2 inhi-
bitors primarily inhibit the production of pros-
taglandin E2, which is a prostaglandin believed to
play an important role in the inflammatory
cascade. In addition, specific COX-2 inhibitors are
reported to have a less inhibitory effect on bone
healing or bone union after a spinal fusion
compared with conventional nonspecific NSAIDs
both in vivo and vitro.
25,26
Ketorolac is a NSAID that has been widely used
for postoperative pain control. It plays an impor-
tant role in decreasing the demand for morphine
which has many potential complications, such as
respiratory depression, addiction, nausea, vomit-
ing, and urinary retention.
9,10,19 Glassman et al.
reported that the fusion rate of a ketorolac
intramuscularly injected group was lower than a
non-ketorolac injected group after a posterolateral
spinal fusion procedure.
14 In this study, the
ketorolac group showed decreased fusion rates
compared with the control group. The ketorolac
group had a high relative risk of non fusion,
approximately 6 times higher than the control
group. Therefore, conventional NSAIDs such as
ketorolac should be avoided after spinal fusion in
order to avoid fusion failures. If it is necessary to
use NSAIDs for postoperative pain control,
specific COX-2 inhibitors are preferred after spine
fusion.
24-27
Cigarette smoking has also been correlated with
poor outcomes in the surgical treatment of a
lumbar spinal disorder and has been shown to
inhibit the lumbar spinal fusion rate approxi-
mately 2 - 3 times than normal. The mechanism of
inhibition of spinal fusion has been identified as
the diminished revascularization of a cancellous
bone graft.
28 In this study, there were 15 patients
who smoked before the spinal fusion, but there
were no spinal nonunion cases in either the
ketorolac injected group or non-ketorolac injected
group, and no correlation could be found betweenSi-Young Park, et al.
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the smoking and spinal fusion rate. We advised
patients who smoked, to quit before their spinal
fusion and remain smoke-free post-operatively, as
smoking cessation before and after spinal fusion
has been reported to have an improved outcome
compared with the continuation of smoking in
other studies.
6,28
The clinical outcomes after posterolateral spinal
fusion may vary. It has been estimated that 50%
of patients with pseudarthrosis have no symp-
toms. There are some reports showing that there
are no differences in the symptoms between
complete fusion cases and pseudarthrosis cases.
However, complete fusion cases have usually
been reported to show better outcomes than those
with pseudarthrosis.
29,30 Similarly, in our study
Group II which did not receive ketorolac showed
better clinical outcomes than Group I and there
was a strong correlation between the spinal fusion
rates and the clinical outcome.
In conclusion, NSAIDs such as ketorolac can be
used for postoperative pain control via PCA to
reduce the need for morphine and avoid its com-
plications. However, ketorolac used via PCA im-
mediate after surgery, inhibits spinal fusion and
shows worse clinical results. Therefore, NSAIDs
such as ketorolac should be avoided after
posterolateral spinal fusion.
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